Polymorphisms in the MTHFR gene: susceptibility to colorectal cancer and role in the response to therapy
Project goals
Polymorphisms in several genes have been indicated as possible susceptibility factors for sporadic colorectal cancer (CRC). Moreover, identification of subgroups of patients that differ in their prognosis and response to treatment suggests that inter-individual differences in the toxicity and response to anticancer therapies is due to their genetic profile. We will investigate the role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR) and in thymidylate synthase (TS) in a population of CRCcases and controls as predictive markers of CRC and response to the therapy. The response to CRC treatment will be evaluated in relation to the role of the analyzed polymorphisms on the selected groups of patients receiving 5-fluorouracil-based chemotherapy and external beam radiotherapy. Present project may contribute to the understanding CRC susceptibility and individual response to chemotherapy and prognosis of patients.
Keywords
Public support
Provider
Czech Science Foundation
Programme
Post-graduate (doctorate) grants
Call for proposals
Postdoktorandské granty 9 (SGA02009GA1PD)
Main participants
—
Contest type
VS - Public tender
Contract ID
305/09/P194
Alternative language
Project name in Czech
Genetické polymorfizmy v genu MTHFR: modulace rizika CRC a vliv na vnímavost k terapii
Annotation in Czech
Cíle předkládaného projektu: a) zkoumat úlohu genetických polymorfizmů v genech MTHFR a TS u populací CRC pacientů a kontrolních skupin jako prediktivních markerů CRC b) zhodnocení možného vztahu mezi uvedenými polymorfizmy v souvislosti s odpovědí na léčbu CRC
Scientific branches
R&D category
ZV - Basic research
CEP classification - main branch
EB - Genetics and molecular biology
CEP - secondary branch
—
CEP - another secondary branch
—
10603 - Genetics and heredity (medical genetics to be 3)
10604 - Reproductive biology (medical aspects to be 3)
10605 - Developmental biology
10608 - Biochemistry and molecular biology
10609 - Biochemical research methods
30101 - Human genetics
Completed project evaluation
Provider evaluation
V - Vynikající výsledky projektu (s mezinárodním významem atd.)
Project results evaluation
The project was excellent, both in terms of expertise and in terms of disbursement of funds.
Solution timeline
Realization period - beginning
Jan 1, 2009
Realization period - end
Dec 31, 2011
Project status
U - Finished project
Latest support payment
Apr 16, 2011
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP12-GA0-GP-U/03:3
Data delivery date
May 2, 2016
Finance
Total approved costs
1,821 thou. CZK
Public financial support
1,821 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK
Basic information
Recognised costs
1 821 CZK thou.
Public support
1 821 CZK thou.
100%
Provider
Czech Science Foundation
CEP
EB - Genetics and molecular biology
Solution period
01. 01. 2009 - 31. 12. 2011